NO20081038L - Farmasoytiske formuleringer/sammensetninger av guanfacin egnet for daglig enkel doseform administrering - Google Patents

Farmasoytiske formuleringer/sammensetninger av guanfacin egnet for daglig enkel doseform administrering

Info

Publication number
NO20081038L
NO20081038L NO20081038A NO20081038A NO20081038L NO 20081038 L NO20081038 L NO 20081038L NO 20081038 A NO20081038 A NO 20081038A NO 20081038 A NO20081038 A NO 20081038A NO 20081038 L NO20081038 L NO 20081038L
Authority
NO
Norway
Prior art keywords
guanfacine
compositions
dosage form
pharmaceutical formulations
single dosage
Prior art date
Application number
NO20081038A
Other languages
English (en)
Norwegian (no)
Inventor
Amir Shojaei
Michael Pennick
Original Assignee
Shire Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37668083&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20081038(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Shire Llc filed Critical Shire Llc
Publication of NO20081038L publication Critical patent/NO20081038L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Addiction (AREA)
  • Pregnancy & Childbirth (AREA)
  • Psychiatry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Psychology (AREA)
  • Anesthesiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO20081038A 2005-07-28 2008-02-27 Farmasoytiske formuleringer/sammensetninger av guanfacin egnet for daglig enkel doseform administrering NO20081038L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US70298205P 2005-07-28 2005-07-28
PCT/US2006/029277 WO2007016284A2 (fr) 2005-07-28 2006-07-27 Preparations/compositions pharmaceutiques de guanfacine destinees a l'administration d'une dose quotidienne unique

Publications (1)

Publication Number Publication Date
NO20081038L true NO20081038L (no) 2008-04-23

Family

ID=37668083

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20081038A NO20081038L (no) 2005-07-28 2008-02-27 Farmasoytiske formuleringer/sammensetninger av guanfacin egnet for daglig enkel doseform administrering

Country Status (18)

Country Link
US (1) US20070048371A1 (fr)
EP (1) EP1909766B1 (fr)
JP (2) JP5726401B2 (fr)
KR (1) KR20080041669A (fr)
CN (1) CN101252917A (fr)
AR (1) AR054595A1 (fr)
AU (1) AU2006275718B8 (fr)
BR (1) BRPI0615989B8 (fr)
CA (1) CA2616181C (fr)
DK (1) DK1909766T3 (fr)
ES (1) ES2566395T3 (fr)
IL (1) IL188980A0 (fr)
NO (1) NO20081038L (fr)
NZ (1) NZ565649A (fr)
RU (1) RU2435573C2 (fr)
TW (1) TW200744672A (fr)
WO (1) WO2007016284A2 (fr)
ZA (1) ZA200801575B (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0916163D0 (en) * 2009-09-15 2009-10-28 Shire Llc Prodrugs of guanfacine
LT2531181T (lt) * 2010-02-03 2019-07-10 Pharma Two B Ltd. Rasagilino uždelsto atpalaidavimo kompozicijos ir jų panaudojimas
AU2011265293A1 (en) * 2010-06-11 2013-01-24 Shire Llc Combination therapy with lisdexamphetamine and extended release guanfacine
US20120041068A1 (en) * 2010-08-11 2012-02-16 Aptapharma, Inc. Extended Release Pharmaceutical Preparations for Active Pharmaceutical Ingredients with pH Dependent Solubility
CN102525983A (zh) * 2010-12-31 2012-07-04 北京万全阳光医药科技有限公司 胍法新缓释片及其制备方法
CN102579381B (zh) * 2012-03-30 2013-07-10 河南中帅医药科技发展有限公司 盐酸胍法辛缓释制剂及其制备方法
EP2968151B1 (fr) * 2013-03-13 2017-04-19 Tris Pharma, Inc. Comprimés et capsules solides à libération modifiée de benzonatate
US9180104B2 (en) * 2013-03-13 2015-11-10 Tris Pharma, Inc. Benzonatate modified release solid tablets and capsules
US10022341B2 (en) 2014-12-02 2018-07-17 Yale University Methods of preventing neurodegeneration of association cortex in a mammal
US20180360761A1 (en) * 2015-12-08 2018-12-20 Ardea Biosciences, Inc. Pharmaceutical composition comprising a potent inhibitor of urat1
JP6656670B2 (ja) * 2016-03-11 2020-03-04 国立大学法人 鹿児島大学 抗ｈｃｖ活性を有する薬剤
RS63558B1 (sr) * 2016-04-20 2022-10-31 New Frontier Labs Llc Estri azelainske kiseline u lečenju insulinske rezistencije
WO2019136224A1 (fr) * 2018-01-05 2019-07-11 Shire Human Genetic Therapies, Inc. Combinaisons d'amphétamine-guanfacine pour le traitement de troubles neuropsychiatriques
TW202400130A (zh) 2022-06-15 2024-01-01 日商澤井製藥股份有限公司 含胍法辛鹽酸鹽製劑

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH649918A5 (de) * 1981-07-09 1985-06-28 Sandoz Ag Verwendung von n-amidino-2-phenylacetamiden als wirkstoff zur herstellung von pharmazeutischen zubereitungen gegen schizophrenie.
IE56999B1 (en) * 1983-12-22 1992-03-11 Elan Corp Plc Pharmaceutical formulation
US5102668A (en) * 1990-10-05 1992-04-07 Kingaform Technology, Inc. Sustained release pharmaceutical preparation using diffusion barriers whose permeabilities change in response to changing pH
US5854290A (en) * 1995-09-21 1998-12-29 Amy F. T. Arnsten Use of guanfacine in the treatment of behavioral disorders
DE19834573A1 (de) * 1998-07-31 2000-02-03 Bayer Ag Doppelmetallcyanid-Katalysatoren für die Herstellung von Polyetherpolyolen
FR2781152B1 (fr) * 1998-07-20 2001-07-06 Permatec Tech Ag Utilisation d'un polymere de type acrylique en tant qu'agent de desagregation
PE20001396A1 (es) * 1999-01-18 2000-12-23 Gruenenthal Chemie Formulaciones medicamentosas retardadas que contienen una combinacion de un opioide o una sal fisiologicamente tolerables del mismo, un o-agonista
US6635277B2 (en) * 2000-04-12 2003-10-21 Wockhardt Limited Composition for pulsatile delivery of diltiazem and process of manufacture
US6287599B1 (en) * 2000-12-20 2001-09-11 Shire Laboratories, Inc. Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles
ES2233876T3 (es) * 2001-12-19 2005-06-16 Astrazeneca Ab Nuevo recubrimiento de pelicula que contiene un copolimero acrilato de etilo/metacrilato de metilo y poli (acetato de vinilo).
US6811794B2 (en) * 2001-12-20 2004-11-02 Shire Laboratories, Inc. Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles
CA2481236A1 (fr) * 2002-03-29 2003-10-09 Alza Corporation Forme de dosage a liberation controlee a volume efficace
US6763509B2 (en) * 2002-09-26 2004-07-13 Sun Microsystems, Inc. Method and apparatus for allocating decoupling capacitor cells
US20070104782A1 (en) * 2005-07-28 2007-05-10 Ibrahim Melissa E Modified release tablet formulations with enhanced mechanical properties

Also Published As

Publication number Publication date
JP5726401B2 (ja) 2015-06-03
BRPI0615989A2 (pt) 2011-05-31
AU2006275718A8 (en) 2012-11-01
EP1909766B1 (fr) 2016-03-16
AR054595A1 (es) 2007-06-27
US20070048371A1 (en) 2007-03-01
AU2006275718B8 (en) 2012-11-01
ZA200801575B (en) 2008-12-31
ES2566395T3 (es) 2016-04-12
AU2006275718B2 (en) 2012-10-04
CA2616181A1 (fr) 2007-02-08
DK1909766T3 (en) 2016-04-04
KR20080041669A (ko) 2008-05-13
EP1909766A2 (fr) 2008-04-16
NZ565649A (en) 2011-03-31
BRPI0615989B1 (pt) 2020-05-26
WO2007016284A3 (fr) 2007-03-29
JP2012229253A (ja) 2012-11-22
RU2008102911A (ru) 2009-09-10
BRPI0615989B8 (pt) 2021-05-25
RU2435573C2 (ru) 2011-12-10
JP2009502951A (ja) 2009-01-29
CN101252917A (zh) 2008-08-27
IL188980A0 (en) 2008-08-07
AU2006275718A1 (en) 2007-02-08
TW200744672A (en) 2007-12-16
WO2007016284A2 (fr) 2007-02-08
CA2616181C (fr) 2015-02-17

Similar Documents

Publication Publication Date Title
NO20081038L (no) Farmasoytiske formuleringer/sammensetninger av guanfacin egnet for daglig enkel doseform administrering
AU2008347158A8 (en) Oral pharmaceutical dosage forms
MA32200B1 (fr) Nouvelles formulations,comprimes comprenant de telles formulations, leur utilisation et leur procede de preparation
SV2009003231A (es) Uso de valerato de estradiol o 17b-estradiol en combinacion con dienogest en una terapia oral para mantener y/o implementar la libido femenina
ECSP10010224A (es) Formulaciones líquidas de hormona luteinizante (lh).
CY1115652T1 (el) Μορφη δοσολογιας που περιεχει δυο δραστικα φαρμακευτικα συστατικα μειγματος σε διαφορετικες φυσικες μορφες
RS51569B (en) COMPOSITIONS CONTAINING CRYSTAL TRANS - (+/-) - DELTA-9-TETRAHYDROCANABINOL
CY1111470T1 (el) Νεες φαρμακευτικες συνθεσεις που περιεχουν φλιβανσερινη πολυμορφη α
UA106636C2 (uk) Морфолінотіазоли як позитивні алостеричні модулятори альфа 7
RS52457B (en) POWDER FORMULATION FOR VALGANCICLOVIR
UA116334C2 (uk) Тверді форми дозування бендамустину
NO20080220L (no) Formuleringer med hoy medikament belastning og doseringsformer
CY1111442T1 (el) Ενωσεις πιπεριδινης και χρησεις αυτων
AR025938A1 (es) Nuevas composiciones farmaceuticas.
EA201170512A1 (ru) Композиция для перорального введения
CR20110704A (es) Composiciones de dosis fija farmacéuticas sólidas que comprenden irbesartán y amilodipina, su preparación y su aplicación terapéutica
DK1987063T3 (da) Peptider og peptidderivater, fremstilling deraf samt deres anvendelse til fremstilling af en terapeutisk og/eller præventivt aktiv farmaceutisk sammensætning
ATE460934T1 (de) Pharmazeutische zubereitungen von ciprofloxacin
DE602007004348D1 (de) Arzneimittel zur behandlung von sarkoglykanopathien
MA31227B1 (fr) Composition pharmaceutique renfermant du phloroglucinol et du paracetamol.
GB0327390D0 (en) Pharmaceutical formulations
TR200704897A1 (tr) Uzatılmış salım sağlayan gliklazid formülasyonları@
AR070886A1 (es) Nuevo regimen de drospirenona /17 beta -estradiol, producto farmaceutico combinado y conjunto de elementos (kit) para su aplicacion
ATE551998T1 (de) Feste pharmazeutische zusammensetzung mit tamsulosin
CU20090062A7 (es) Uso de valerato de estradiol o 17beta-estradiol en combinación con dienogest en una terapia oral para mantener y/o incrementar la líbido femenina

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application